Thus ERG11 point mutations resulting in 16 different amino acid substitutions were detected among the 25 test Sapanisertib Isolates by RCA (Table 2) whereas 20 substitutions were identified by DNA sequencing. Sequencing identified that all amino acid substitutions were due to homozygous nucleotide polymorphisms. Table 3 Additional amino acid substitutions identified by ERG11 sequencing in five C. albicans isolates with reduced susceptibility to fluconazole. Patient/isolate no. Substitutions detected by RCA Substitutions detected by DNA sequencing 5 G307S G307S, G450V 6-Aa E266D E266D,

D153E 6-Ba D116E D116E, D153E 10 E266D, V488I, Selleckchem GDC 0032 S405F, Y132H E266D, V488I, S405F, Y132H, K108E 11 E266D, V437I E266D, V437I, F126L 12-Aa G464S G464S, K108E a The “”A”" and “”B”" notation of patient numbers refers to isolates which were cultured sequentially from the same patient at different times. The substitution G464S was present in four isolates, G448E and G307S were present in three isolates each and the substitutions Y132H, S405F and R467K

(each n = 1) were rare (Table 2). Of note, five of the 10 ERG11 mutations (leading to amino acid substitutions A61V, G450E, H238R, R467I and Y257H) present in “”reference”" isolates from the United States (Table 1) were not detected selleck inhibitor in Australian isolates. Overall, the most frequently-identified substitutions were E266D (n = 11 isolates) followed by V488I (n = 8), D116E (n = 8) and K128T (n = 7). Nineteen of the 20 mutations (95%) were clustered in three regions of Erg11p: positions 105–165, 266–287 and 405–488 (Table 2). Sequential

isolates were available from five patients (patients 3 6, 8, 12 and 16). Isolates from patients 3 and 8 had similar ERG11 mutation and MIC profiles; however, isolates from patient 16 demonstrated a step-wise increase in voriconazole MICs in parallel with additional amino acid substitutions; the isolate with the highest MIC contained five substitutions while the isolate with the lowest MIC contained three (Table 2). Conversely, Y-27632 2HCl for patient 12, one additional mutation was present from the analysis of the second isolate (isolate 12B; see also Table 3) but the fluconazole and voriconazole MICs of this isolate were lower than that for isolate 12A. Both isolates from patient 6 had similar azole MICs but had one different ERG11 mutation (Tables 2 and Table 3). Fluconazole-susceptible isolates No ERG11 mutations were detected by either RCA or ERG11 sequencing in five of the 23 (22%) fluconazole-susceptible isolates. In the other 18, five amino acid substitutions namely E266D (n = 15 isolates), D116E (n = 11), V488I (n = 7), K128T (n = 3) and V437I (n = 2) were identified (Table 2).